Portfolio company
GenSight Biologics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops gene therapies for patients suffering from neurodegenerative retinal diseases and central nervous system disorders.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Nightstar
This company develops gene therapies for patients with rare inherited retinal diseases that cause progressive blindness.
Atsena
This clinical-stage gene therapy company develops genetic medicines to reverse or prevent blindness for patients with inherited retinal diseases.
Coave Therapeutics
The company develops targeted gene therapies for patients with neurodegenerative and ocular diseases.
Beacon Therapeutics
This company develops ophthalmic gene therapies to restore vision for patients with rare and prevalent retinal diseases causing blindness.
PulseSight Therapeutics
This company develops non-viral gene therapies for patients with severe eye diseases including age-related macular degeneration.
Ray Therapeutics
The company develops optogenetic gene therapies to restore vision for patients with blinding retinal diseases.
4DMT
This company develops targeted gene therapy medicines for patients with severe genetic and retinal diseases.
Sensorion
This company develops gene therapies and small molecule drugs to restore, treat and prevent inner ear disorders for patients with hearing loss.